Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2596 to 2610 of 8901 results

  1. Trastuzumab deruxtecan for neoadjuvant treatment of HER2-positive early breast cancer [ID6620]

    Awaiting development Reference number: GID-TA11403 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Digital technologies to support self-management of asthma: early value assessment

    In development Reference number: GID-HTE10063 Expected publication date:  30 April 2026

    Health technology evaluations
    In development

  3. Aficamten for treating symptomatic obstructive hypertrophic cardiomyopathy [ID6575]

    In development Reference number: GID-TA11742 Expected publication date:  05 August 2026

    Technology appraisal guidance
    In development

  4. Digital technologies for applying algorithms to spirometry to support asthma and COPD diagnosis in primary care and community diagnostic centres: early-use assessment

    In development Reference number: GID-HTE10065 Expected publication date:  02 April 2026

    Health technology evaluations
    In development

  5. 12 SQ-HDM SLIT for treating allergic rhinitis caused by house dust mites in children 5 to 11 years [ID6510]

    In development Reference number: GID-TA11635 Expected publication date:  26 August 2026

    Technology appraisal guidance
    In development

  6. MRI-guided focused ultrasound thalamotomy for treatment-resistant essential tremor

    In development Reference number: GID-IPG10441 Expected publication date: TBC

    Interventional procedures guidance
    In development

  7. MRI-guided focused ultrasound thalamotomy for treatment-resistant essential tremor: draft scope consultation

    We are listening to your views on this Interventional procedures guidance. Comments close 11 February 2026.

    Interventional procedures guidance
    In consultation

  8. Aggressive behaviour in people receiving NHS or social care: prevention and management

    In development Reference number: GID-NG10432 Expected publication date:  28 January 2027

    NICE guideline
    In development

  9. Mirdametinib for treating symptomatic inoperable plexiform neurofibromas in people 2 years and over with neurofibromatosis type 1 [ID6618]

    In development Reference number: GID-TA11819 Expected publication date:  03 September 2026

    Technology appraisal guidance
    In development

  10. Ibrutinib for treating relapsed or refractory follicular lymphoma [ID1251]

    In development Reference number: GID-TA10223 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. CT hepatic arteriography for patients undergoing percutaneous ablation of primary or secondary liver tumours

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  12. Ibrutinib with R-CHOP for untreated mantle cell lymphoma when an autologous stem cell transplant is suitable [ID6596]

    In development Reference number: GID-TA11802 Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Icotrokinra for treating moderate to severe plaque psoriasis in people 12 years and over [ID6579]

    In development Reference number: GID-TA11780 Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Enfortumab vedotin with pembrolizumab for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer [ID6607]

    In development Reference number: GID-TA11694 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Cemiplimab for treating recurrent or metastatic cervical cancer that has progressed on or after platinum-based chemotherapy (review of TA901) [ID6610]

    In development Reference number: GID-TA11850 Expected publication date:  03 September 2026

    Technology appraisal guidance
    In development